Breaking News Instant updates and real-time market news.

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23

Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2

Apellis Pharmaceuticals announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia, including cold agglutinin disease and warm antibody autoimmune hemolytic anemia. Data from the PLAUDIT trial will be presented in an oral presentation at the 24th Annual Congress of the European Hematology Association, held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test C3+; 5 of the C3+ wAIHA patients have been on APL-2 for at least 168 days. Of the 10 patients who reached Day 168: 70% showed a Hb increase of greater than or equal to2 g/dL, 40% had normalized Hb and 80% had Hb greater than or equal to11.0 g/dL at Day 168. Mean Hb increased from 8.9 g/dL at baseline to 11.2 g/dL at Day 168, a 2.4 g/dL increase. Mean Functional Assessment of Chronic Illness Therapy Fatigue Score increased from 29.4 at baseline to 39.1 at Day 168, an improvement of 9.7 points, where a clinically significant increase is 3 or more points. Mean absolute reticulocyte count decreased from 159 X 10/L at baseline to 64 X 10/L at Day 168. Mean indirect bilirubin decreased from 1.6 mg/dL at baseline to 0.4 mg/dL at Day 168. Mean LDH decreased from 500 U/L at baseline to 183 U/L at Day 168. Two heavily transfusion dependent patients did not respond to APL-2 and left the study at Day 56 and 108 respectively. The remaining transfusion dependent patients did not require any transfusions during maintenance treatment with APL-2. One previously non-transfusion dependent patient received an on-study transfusion prior to APL-2 steady-state. One patient is still participating in the study and has not yet reached Day 168. Of the 5 patients with C3+ wAIHA who reached Day 168: Mean Hb increased from 9.0 g/dL at baseline to 11.0 g/dL at Day 168, a 2.0 g/dL increase. Mean FACIT Fatigue Score increased from 38.4 at baseline to 40.8 at Day 168, an improvement of 2.4 points. Mean ARC decreased from 213 X 10/L at baseline to 92 X 10/L at Day 168. Mean indirect bilirubin decreased from 0.8 mg/dL at baseline to 0.3 mg/dL at Day 168. Mean LDH decreased from 241 U/L at baseline to 142 U/L at Day 168. Two of the eight enrolled C3+ wAIHA patients left the study due to lack of response, and one of the eight enrolled C3+ wAIHA subjects is still participating in the study and has not yet reached Day 168. The three enrolled patients who were not DAT C3+ did not show a meaningful response and two have left the study. In both the CAD and C3+ wAIHA populations, APL-2 was generally well tolerated; no serious adverse events related to APL-2 were reported in the PLAUDIT trial. In both the CAD and C3+ wAIHA populations, APL-2 was generally well tolerated; no serious adverse events related to APL-2 were reported in the PLAUDIT trial.

  • 18

    Jun

APLS Apellis
$21.22

-0.14 (-0.66%)

01/23/19
JPMS
01/23/19
DOWNGRADE
Target $34
JPMS
Neutral
JPMorgan downgrades Apellis to Neutral with no data until Q4
JPMorgan analyst Anupam Rama downgraded Apellis Pharmaceuticals to Neutral from Overweight with an unchanged price target of $34. The analyst continues to like the shares long term and view APL-2 as an underappreciated asset in the complement space. However, with data not out until Q4, the analyst expects Apellis shares to perform in line with the market in the first half of 2019.
03/28/19
BARD
03/28/19
INITIATION
Target $45
BARD
Outperform
Apellis initiated with an Outperform at Baird
Baird started Apellis Pharmaceuticals with an Outperform rating and $45 price target.
03/28/19
BARD
03/28/19
INITIATION
Target $45
BARD
Outperform
Apellis initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Apellis with an Outperform rating and a price target of $45. The analyst says the company's lead asset, complement C3 inhibitor APL-2, has the "potential to disrupt multiple diseases, including the ophthalmologic market of geographic atrophy and orphan disease market of paroxysmal nocturnal hemoglobinuria". Kumar sees Apellis' top-line data from the Phase 3 PEGASUS trial in paroxysmal nocturnal hemoglobinuria as a "key near-term catalyst" for its shares.
03/29/19
03/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Etsy (ETSY) initiated with a Perform at Oppenheimer. 2. Apellis (APLS) and uniQure (QURE) initiated with an Outperform at Baird. 3. BRT Apartments (BRT) initiated with a Buy at DA Davidson. 4. Lilis Energy (LLEX) initiated with an Equal Weight at Stephens. 5. Outfront Media (OUT) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CRM

Salesforce

$148.26

0.86 (0.58%)

08:16
08/23/19
08/23
08:16
08/23/19
08:16
Recommendations
Salesforce analyst commentary  »

Salesforce remains best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

08:15
08/23/19
08/23
08:15
08/23/19
08:15
General news
Fed's Bullard expects a robust debate on 25 bps versus 50 bps »

Fed's Bullard…

NXTD

Nxt-ID

$0.35

-0.0099 (-2.79%)

08:13
08/23/19
08/23
08:13
08/23/19
08:13
Downgrade
Nxt-ID rating change  »

Nxt-ID downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCAT

Health Catalyst

$43.00

-0.5 (-1.15%)

08:12
08/23/19
08/23
08:12
08/23/19
08:12
Earnings
Health Catalyst sees FY19 revenue $149.8M-$151.8M »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRXPF

Crop Infrastructure

$0.00

(0.00%)

08:11
08/23/19
08/23
08:11
08/23/19
08:11
Hot Stocks
Crop Infrastructure announces completion of first California greenhouse harvest »

CROP Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCAT

Health Catalyst

$43.00

-0.5 (-1.15%)

08:11
08/23/19
08/23
08:11
08/23/19
08:11
Earnings
Health Catalyst sees Q3 revenue $36.8M-$38.8M »

Sees Q3 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCAT

Health Catalyst

$43.00

-0.5 (-1.15%)

08:10
08/23/19
08/23
08:10
08/23/19
08:10
Earnings
Health Catalyst reports Q2 pro forma adjusted EPS (21c) »

Reports Q2 revenue $36.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCRH

QCR Holdings

$35.88

-0.24 (-0.66%)

, DE

Deere

$155.49

0.65 (0.42%)

08:08
08/23/19
08/23
08:08
08/23/19
08:08
Hot Stocks
QCR Holdings appoints James Field as independent director »

QCR Holdings (QCRH)…

QCRH

QCR Holdings

$35.88

-0.24 (-0.66%)

DE

Deere

$155.49

0.65 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

BYSI

BeyondSpring

$16.50

-0.47 (-2.77%)

08:06
08/23/19
08/23
08:06
08/23/19
08:06
Hot Stocks
BeyondSpring says Plinabulin shows superior QoL over Pegfilgrastim in trial »

BeyondSpring announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.03

-0.01 (-0.11%)

, GM

General Motors

$37.25

0.14 (0.38%)

08:06
08/23/19
08/23
08:06
08/23/19
08:06
Periodicals
China to resume 25% tariffs on U.S. autos from December 15, Bloomberg says »

Publicly traded…

F

Ford

$9.03

-0.01 (-0.11%)

GM

General Motors

$37.25

0.14 (0.38%)

HMC

Honda

$23.22

-0.07 (-0.30%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$129.63

-0.39 (-0.30%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.77

0.05 (0.39%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

SPY

SPDR S&P 500 ETF Trust

$292.36

-0.04 (-0.01%)

, SPX

S&P 500

$0.00

(0.00%)

08:05
08/23/19
08/23
08:05
08/23/19
08:05
General news
China to levy 5%-10% retaliatory tariffs on $75B of U.S. imports, Bloomberg says »

China said it will levy…

SPY

SPDR S&P 500 ETF Trust

$292.36

-0.04 (-0.01%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$95.55

-0.35 (-0.36%)

, BREW

Craft Brew

$13.03

0.56 (4.49%)

08:04
08/23/19
08/23
08:04
08/23/19
08:04
Hot Stocks
Anheuser-Busch says not making offer to purchase remaining shares of CBA »

Anheuser-Busch released…

BUD

AB InBev

$95.55

-0.35 (-0.36%)

BREW

Craft Brew

$13.03

0.56 (4.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 25

    Oct

  • 12

    Nov

INGN

Inogen

$44.77

1.49 (3.44%)

08:04
08/23/19
08/23
08:04
08/23/19
08:04
Conference/Events
Inogen participates in a conference call with SVB Leerink »

SVB Leerink holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 09

    Sep

  • 10

    Sep

BREW

Craft Brew

$13.03

0.56 (4.49%)

, BUD

AB InBev

$95.55

-0.35 (-0.36%)

08:03
08/23/19
08/23
08:03
08/23/19
08:03
Hot Stocks
Craft Brew confirms it will receive $20M incentive payment from Anheuser-Busch »

Craft Brew Alliance…

BREW

Craft Brew

$13.03

0.56 (4.49%)

BUD

AB InBev

$95.55

-0.35 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 25

    Oct

  • 12

    Nov

TSCO

Tractor Supply

$101.11

0.18 (0.18%)

08:03
08/23/19
08/23
08:03
08/23/19
08:03
Hot Stocks
Tractor Supply COO Steve Barbarick resigns »

The Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 24

    Oct

  • 13

    Nov

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

08:03
08/23/19
08/23
08:03
08/23/19
08:03
Recommendations
HP Inc. analyst commentary  »

HP Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

TSCO

Tractor Supply

$101.11

0.18 (0.18%)

08:02
08/23/19
08/23
08:02
08/23/19
08:02
Hot Stocks
Tractor Supply extends employment contract with CEO Greg Sandfort »

Tractor Supply Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 24

    Oct

  • 13

    Nov

TENX

Tenax Therapeutics

$1.18

(0.00%)

08:02
08/23/19
08/23
08:02
08/23/19
08:02
Hot Stocks
Tenax Therapeutics provides levosimendan clinical trial update »

Tenax Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$7.65

-0.61 (-7.39%)

08:02
08/23/19
08/23
08:02
08/23/19
08:02
Hot Stocks
Qudian announces $195M forward share repurchase plan »

Qudian announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 06

    Sep

SPLK

Splunk

$118.43

-10.08 (-7.84%)

08:00
08/23/19
08/23
08:00
08/23/19
08:00
Recommendations
Splunk analyst commentary at Argus »

Splunk may become an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 15

    Oct

ATRC

AtriCure

$26.74

-0.46 (-1.69%)

08:00
08/23/19
08/23
08:00
08/23/19
08:00
Conference/Events
AtriCure participates in a conference call with SVB Leerink »

SVB Leerink holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 17

    Sep

  • 18

    Sep

07:55
08/23/19
08/23
07:55
08/23/19
07:55
General news
Fed's Bullard remains worried about low inflation and downside risks to the economy »

Fed's Bullard…

AMRC

Ameresco

$14.62

-0.11 (-0.75%)

07:54
08/23/19
08/23
07:54
08/23/19
07:54
Conference/Events
Cowen alternative energy analyst to hold analyst/industry conference call »

Alternative Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

ATGE

Adtalem Global Education

$50.93

-0.37 (-0.72%)

07:54
08/23/19
08/23
07:54
08/23/19
07:54
Recommendations
Adtalem Global Education analyst commentary at BMO Capital »

Adtalem Global Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

CERN

Cerner

$71.62

-0.15 (-0.21%)

07:52
08/23/19
08/23
07:52
08/23/19
07:52
Downgrade
Cerner rating change at Jefferies »

Cerner downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.